Narrow Substrate Specificity and Sensitivity toward Ligand-binding Site Mutations of Human T-cell Leukemia Virus Type 1 Protease by Kádas, János et al.
Narrow Substrate Specificity and Sensitivity toward Ligand-binding
Site Mutations of Human T-cell Leukemia Virus Type 1 Protease*
Received for publication, February 20, 2004, and in revised form, April 13, 2004
Published, JBC Papers in Press, April 20, 2004, DOI 10.1074/jbc.M401868200
Ja´nos Ka´das‡, Irene T. Weber§, Pe´ter Bagossi‡, Gabriella Miklo´ssy‡, Pe´ter Boross‡,
Stephen Oroszlan¶, and Jo´zsef To¨zse´r‡
From the ‡Department of Biochemistry and Molecular Biology, Research Center for Molecular Medicine, Medical and
Health Science Center, University of Debrecen, H-4012 Debrecen, P. O. Box 6, Hungary, the §Department of Biology,
Georgia State University, Atlanta, Georgia 30303, and ¶HIV Drug Resistance Program, NCI-Frederick,
National Institutes of Health, Frederick, Maryland 21702-1201
Human T-cell leukemia virus type 1 (HTLV-1) is asso-
ciated with a number of human diseases; therefore, its
protease is a potential target for chemotherapy. To com-
pare the specificity of HTLV-1 protease with that of
human immunodeficiency virus type 1 (HIV-1) protease,
oligopeptides representing naturally occurring cleav-
age sites in various retroviruses were tested. The num-
ber of hydrolyzed peptides as well as the specificity
constants suggested a substantially broader specificity
of the HIV protease. Amino acid residues of HTLV-1
protease substrate-binding sites were replaced by
equivalent ones of HIV-1 protease. Most of the single and
multiple mutants had altered specificity and a dramat-
ically reduced folding and catalytic capability, suggest-
ing that mutations are not well tolerated in HTLV-1
protease. The catalytically most efficient mutant was
that with the flap residues of HIV-1 protease. The inhi-
bition profile of the mutants was also determined for
five inhibitors used in clinical practice and inhibitor
analogs of HTLV-1 cleavage sites. Except for indinavir,
the HIV-1 protease inhibitors did not inhibit wild type
and most of the mutant HTLV-1 proteases. The wild type
HTLV-1 protease was inhibited by the reduced peptide
bond-containing substrate analogs, whereas the mu-
tants showed various degrees of weakened binding ca-
pability. Most interesting, the enzyme with HIV-1-like
residues in the flap region was the most sensitive to the
HIV-1 protease inhibitors and least sensitive to the
HTLV-1 protease inhibitors, indicating that the flap
plays an important role in defining the specificity dif-
ferences of retroviral proteases.
The retroviral protease (PR)1 is responsible for the process-
ing of viral Gag and Gag-Pro-pol polyproteins during matura-
tion, hence catalyzing essential steps of virion replication (for a
review, see Ref. 1). Therefore, the HIV-1 PR has proved to be an
effective target for antiretroviral therapy of AIDS, and various
PR inhibitors are in clinical use (reviewed in Ref. 2). However,
the continual emergence of viral variants that are cross-resis-
tant to the existing inhibitors of PR indicates that there is a
need for new, broad spectrum PR inhibitors (3). Mutations at
more than 20 positions of the 99-residue-long HIV-1 PR have
been associated with resistance (4). Residues that confer inhib-
itor resistance to HIV-1 PR are frequently seen in equivalent
positions of other retroviral PRs, as demonstrated in case of
HTLV-1 PR (5). Therefore, understanding the specificity differ-
ences of PRs may help the design of inhibitors effective against
the mutant HIV-1 PR forms appearing in resistance.
HTLV-1 is a retrovirus that has been etiologically associated
with a number of diseases including adult T-cell leukemia and
HTLV-1-associated myelopathy (reviewed in Ref. 6). Studies
indicated that blocking viral replication with azidothymidine
or lamivudine could have a therapeutic effect (7). HTLV-1,
together with HTLV-2, simian T-cell lymphotropic viruses, and
bovine leukemia virus (BLV), is a member of the deltaretrovi-
rus genus (8). HTLV-1 PR, like HIV-1 PR, is a homodimeric
aspartyl protease, but each monomer comprises 125 residues
(Fig. 1A). Studies on the HTLV-1 PR have been reviewed re-
cently (9). Although HTLV-1 PR shares 28% sequence identity
with HIV-1 PR, based on a molecular model of the enzyme (10),
the substrate binding region is more conserved showing 45%
sequence identity. Nevertheless, both the substrate specificity
and inhibition profile of the two enzymes are substantially
different (5, 9–12). Like all other retroviral PRs studied, the
HTLV-1 PR displays a high degree of specificity, which is
mediated by interactions between side chains of substrate
amino acids and corresponding subsite pockets within the ho-
modimeric enzyme. HTLV-1 PR recognizes at least eight amino
acid residues of the substrate, spanning from P5 to P3 (see Ref.
10, notation is according to Ref. 13).
Several comparative studies have been performed on wild
type retroviral proteases; however, most of them were done on
oligopeptide substrates representing naturally occurring cleav-
age sites in the same viruses or selected peptides having vari-
ous amino acid substitutions (for a review see Ref. 14). In a few
studies oligopeptides representing cleavage sites in other ret-
roviruses were also probed (for example Refs. 15 and 16). How-
ever, no comprehensive studies have been performed between
two proteases by using a library of oligopeptide substrates
* This work was supported in part by Hungarian Science and Re-
search Funds OTKA T 43482, F 35191, and F 34492, by United States
Public Health Service Grant GM62920 from the National Institutes of
Health, and by AIDS FIRCA Grant TW01001. The costs of publication
of this article were defrayed in part by the payment of page charges.
This article must therefore be hereby marked “advertisement” in ac-
cordance with 18 U.S.C. Section 1734 solely to indicate this fact.
 To whom correspondence should be addressed: Dept. of Biochemis-
try and Molecular Biology, Medical and Health Science Center, Univer-
sity of Debrecen, H-4012 Debrecen, P. O. Box 6, Hungary. Tel.: 36-52-
416-432; Fax: 36-52-314-989; E-mail: tozser@indi.biochem.dote.hu.
1 The abbreviations used are: PR, protease; BLV, bovine leukemia
virus; EIAV, equine infectious anemia virus; FIV, feline immunodefi-
ciency virus; HIV-1 and HIV-2, human immunodeficiency virus type 1
and type 2; HTLV-1, human T-cell leukemia virus type 1; MMLV,
Moloney murine leukemia virus; RSV, Rous sarcoma virus; MMTV,
mouse mammary tumor virus; SIV, simian immunodeficiency virus;
MBP, maltose-binding protein; DTT, dithiothreitol; HPLC, high pres-
sure liquid chromatography; Pipes, 1,4-piperazinediethanesulfonic
acid.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 26, Issue of June 25, pp. 27148–27157, 2004
Printed in U.S.A.
This paper is available on line at http://www.jbc.org27148
 at UNIVERSITY O









representing cleavage sites in several different retroviruses.
Such studies may provide important knowledge about the com-
mon characteristics and differences of the PR specificity.
The substrate specificity and inhibitor susceptibility of var-
ious retroviral PRs have also been studied by introducing sin-
gle or multiple mutations into the substrate-binding sites of the
enzymes. Besides the HIV-1 PR, which is typically studied by
introducing mutations appearing in resistance (17–20), HIV-2
PR (21), Rous sarcoma virus (RSV) PR (22, 23), murine leuke-
mia virus (MMLV) PR (24), feline immunodeficiency virus
(FIV) PR (25), and equine infectious anemia virus (EIAV) PR
(26) were studied by using this approach. On the other hand, no
substrate-binding site mutants of HTLV-1 or any other delt-
aretroviral protease have been described so far in the literature
(9); the only mutant HTLV-1 PRs reported so far contained the
stabilizing L40I, C90A, and C109A mutations and showed
specificity and activity indistinguishable from the wild type
enzyme (5).
To study the basis of substrate and inhibitor specificity of
HTLV-1 PR, we used a large set of oligopeptide substrates
representing naturally occurring cleavage sites of various ret-
roviruses. All of these substrates were previously verified to be
a substrate of PR of the respective retrovirus. Furthermore, the
residues of the substrate-binding pockets of the enzyme were
replaced with structurally equivalent residues of HIV-1 PR by
site-directed mutagenesis. Because the S4-binding site ap-
peared to be one of the major determinants of PR specificity
(27), the size of this pocket was systematically changed by
mutation of a key residue. Results were analyzed by using
crystal structures as well as molecular models of the enzymes
and by comparing the results to those obtained with mutagen-
esis studies on other retroviral PRs.
EXPERIMENTAL PROCEDURES
Enzyme Purification—Stabilized wild type HIV-1 and HTLV-1 PRs
were prepared from inclusion bodies as described previously (5, 28).
Mutant HTLV-1 PRs were purified by using the same procedure. The
reversed-phase HPLC-purified enzymes were homogeneous based on
SDS-PAGE. Folding of the enzymes was performed by dialysis of the
HPLC fractions in large excess of 25 mM formic acid, pH 2.8, and
subsequently into 50 mM sodium acetate buffer, pH 5.0, 1 mM DTT, 1
mM EDTA. Finally, the enzymes were dialyzed against 20 mM Pipes, pH
7.0, containing 1 mM EDTA, 100 mM NaCl, 10% glycerol, 5% ethylene
glycol, 0.5% Nonidet P-40, and 10 mM DTT to increase the stability of
the PR preparation. Amino acid composition and protein amount of the
enzymes were determined by amino acid analyses with a Beckman 6300
amino acid analyzer. Active site titration for the HIV-1 PR was per-
formed with Compound 3, a phosphinate group containing tight binding
inhibitors of the enzyme (29). Active site titration of the wild type and
some mutant HTLV-1 PRs was performed by using peptide KTKVL-r-
VVQPK (IB268), where r represents a reduced peptide bond. Reduced
peptide bond-containing inhibitors used in this study (IB268 and IB269,
APQVL-r-PVMHP) were synthesized by Dr. Ivo Blaha (Ferring Leciva,
Prague, Czech Republic).
Assays with Oligopeptide Substrates—The PR assays were initiated
by the mixing of 5 l (8–8500 nM) of purified HTLV-1 or HIV-1 PR with
10 l of 2 incubation buffer (0.5 M potassium phosphate buffer, pH 5.6,
containing 10% glycerol, 2 mM EDTA, 10 mM dithiothreitol, 4 M NaCl)
and 5 l of 0.01–3.0 mM substrate. The synthesis and characterization
of the oligopeptide substrates were described earlier (15, 16, 30–33).
The substrate concentration range was selected depending on the ap-
proximate Km values. The reaction mixture was incubated at 37 °C for
1 h, and the reaction was stopped by the addition of 180 l of 1%
trifluoroacetic acid, and an aliquot was injected onto a Nova-Pak C18
reversed-phase chromatography column (3.9  150 mm, Waters) by
using an automatic injector. Substrates and the cleavage products were
separated by using an increasing water/acetonitrile gradient (0–100%)
in the presence of 0.05% trifluoroacetic acid. Amino acid analysis of the
collected peaks was used to confirm the site of cleavage with at least one
PR (typically with the PR of the same retrovirus) and to quantitate the
amount of substrate cleaved; for other proteases the site of cleavage was
assumed to be identical if cleavage products eluted with the same
retention time and gave the same relative integration values as those
identified by analysis. Kinetic parameters were determined by fitting
the data obtained at less than 20% substrate hydrolysis to the Michae-
lis-Menten equation (or by linear fitting for kcat/Km values determined
under pseudo first-order conditions) by using the Fig. P program (Fig. P
Software Corp.). The standard errors of the kinetic parameters were
below 20%. To test whether the noncleavable peptides representing the
naturally occurring cleavage sites could bind to the enzymes, equal
concentrations (0.2 mM in assay) of the HTLV-1 capsid2nucleocapsid
substrate and the noncleavable peptide were incubated as described
above. If more than 10% inhibition was observed, the IC50 values for the
inhibition were determined by varying the concentration of the inhibi-
tory peptide, and the Ki values were calculated according to Williams
and Morrison (34). The standard errors of the Ki values were below 15%.
To assay the HIV-1 and HTLV-1 PR inhibitors, a microtiter plate
reader assay using fluorescent Dabcyl/Edans-tagged analog of the
capsid2nucleocapsid substrate was used (RE(Edans)TKVL2VVQPK-
(Dabcyl)R, where the arrow represents the cleavable bond) (35). Briefly,
enzyme, substrate, and inhibitor were incubated in 250 mM phosphate
buffer, pH 5.6, containing 5% glycerol, 1 mM EDTA, 5 mM DTT, 500 mM
NaCl, 1% Me2SO in 96-well microtiter plates. The increase of fluo-
rescence was detected at 460 nm, using 355 nm excitation wavelengths
in a Victor Wallace fluorimeter-luminometer and corrected with the
inner filter effect. Ki values were calculated according to Williams and
Morrison (34).
Mutagenesis of the HTLV-1 Protease—The clone coding for the sta-
bilized HTLV-1 PR in a pET expression vector (5) was used as template
for the mutagenesis. Mutants were generated by the Quick-Change
mutagenesis protocol (Stratagene) with the appropriate oligonucleotide
pairs obtained from Genosys-Sigma. Mutations were verified by DNA
sequencing performed with ABI-Prism dye terminator cycle sequencing
kit (PerkinElmer Life Sciences) and an Applied Biosystems model
373A sequencer.
Expression of the Wild Type and Mutant HTLV Proteases as MBP
Fusion Proteins—HTLV-1 PR coding region and an 8-residue-long N-
terminal flanking sequence of an infectious HTLV-1 clone, pCS-HTLV-1
(36), was amplified by PCR and was cloned into the EcoRI/BamHI
restriction sites of pMal-c2 in-frame with the maltose-binding protein
(MBP) coding sequence. The internal HTLV protease sequence (resi-
dues 12–116 of the mature PR, see Fig. 1A) was exchanged with the
sequence of the HTLV-1 PR coding pET expression vector containing
the stabilizing mutations by using PacI and EcoNI restriction sites.
Ligations and transformation of DH5 cells were performed by using
standard protocols (37). Individual mutations were introduced into the
expression clone by using the same oligonucleotide pairs and protocol as
described for the pET clones, and all vectors used for protein expression
were verified by DNA sequencing. Protein expression was induced by
the addition of 1 mM isopropyl--D-thiogalactopyranoside for 3 h. After
expression, cells were collected by centrifugation and lysed in 50 mM
Tris-HCl, pH 8.2, containing 1 mM EDTA, 1 mM DTT, 1% Triton X-100
with sonication. Protein samples were separated by SDS-PAGE and
transferred to polyvinylidene fluoride membrane according to Towbin et
al. (38). Immunoblots were developed using a mixture of antisera of
rabbits immunized against peptides having the N-terminal and C-
terminal sequences of the HTLV-1 protease, a peroxidase-conjugated
anti-rabbit antibody, and an ECL detection kit (Pierce).
Molecular Modeling—The molecular model of wild type HTLV-1 PR
with peptide substrate TKVL2VVQP was built by using the crystal
structure of the RSV S9 mutant as described previously (10). A high
resolution HIV-1 PR-inhibitor complex (Protein Data Bank code 1fgc,
Ref. 28), an RSV PR crystal structure (Protein Data Bank code 2rsp,
Ref. 39), an HIV-2 PR crystal structure (Protein Data Bank code
2mip, Ref. 40), a simian immunodeficiency virus (SIV) PR crystal struc-
ture (Protein Data Bank code 1siv, Ref. 41), an EIAV PR crystal struc-
ture (Protein Data Bank code 1fmb, Ref. 42), and an FIV PR crystal
structure (Protein Data Bank code 1fiv, Ref. 43) were used for compar-
ison. Structural models were examined on a personal computer using
AMMP (44) and RASMOL (45) or a Silicon Graphics work station using
CHAIN (46) or Sybyl (Tripos Inc.).
RESULTS
Comparison of the Substrate Specificity of HTLV-1 and
HIV-1 Proteases Using Oligopeptides Representing Naturally
Occurring Cleavage Sites in Retroviruses—To compare the
specificity of the two proteases, a large set of 50 oligopeptides
representing naturally occurring cleavage sites in HIV-1,
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HIV-2, EIAV, RSV, MMTV, MMLV, BLV, and HTLV-1 were
used. The selected peptides were characterized previously and
were found to be hydrolyzed by the respective protease coded
within the same virus (15, 16, 30–33). Only a few peptides were
cleaved by appreciable kinetics with both HIV and HTLV-1
proteases. Although most PR cleavage sites contain hydropho-
bic residues at P1 and P1, with one exception a common
characteristic of those peptides, which were substrates for both
enzymes, is having hydrophobic -branched residue (Val or Ile)
at P2 and also a hydrophobic -branched residue or Leu at P2
positions. These are typical arrangements for the naturally
occurring HTLV-1 cleavage sites and to a lesser extent for the
BLV cleavage sites (see Table I). Three peptides were hydro-
lyzed only by the HTLV-1 PR but not by HIV-1 PR. On the
other hand, HIV-1 PR was able to cleave many peptides, which
were not substrates of the HTLV-1 PR. In most cases the lack
of hydrolysis by the proteases could be attributed to the inef-
ficient binding of the substrates, because only one noncleaved
TABLE I
Comparison of the specificity of HTLV-1 and HIV-1 proteinases with peptides representing naturally occurring cleavage sites in various viruses
The abbreviations used are as follows: CA, capsid protein; NC, nucleocapsid protein; MA, matrix protein. MPMV, Mason-Pfizer monkey virus;
RT, reverse transcriptase; IN, integrase.
No. Virus sitea Substrate sequence HTLV-1 PR kcat/Km HIV-1 PR kcat/Km
mM1 s1
1 HIV-1 MA2CA VSQNY2PIVQ 0 45.3b
2 HIV-1 CA2p2 KARVL2AEAMS 0 90.0b
3 HIV-1 p22NC TATIM2MQRGN 0 74.0b
4 HIV-1 NC2p1 ERQAN2FLGKI 0 1.0c
5 HIV-1 p12p6 RPGNF2LQSRP 0 0.6b
6 HIV-1 in p6 DKELY2PLTSL 0.02d 0.02b
7 HIV-1 TF2PR VSFNF2PQITL 0 6.9b
8 HIV-1 PR2RT AETF2YVDGAA 0 10.0b
9 HIV-1 RT2RH CTLNF2PISP 0 24.1b
10 HIV-1 RT2IN IRKIL2FLDG 8.4d 202.0b
11 HIV-2 MA2CA KGGNY2PVQHV 0 0.03
12 HIV-2 CA2p2 KARLM2AEALK 0 2.3b
13 HIV-2 p22NC IPFAA2AQQRK 2.6 1.1b
14 HIV-2 NC2p6 KPRNF2PVAQV 0 0.6b
15 HIV-2 TF2PR RGLAA2PQFSL 0 14.6b
16 HIV-2 PR2RT MSLNL2PVAKV 0 110.0b
17 HIV-2 RT2IN IRQVL2FLEKI 113.6 58.0b
18 EIAV MA2CA PSEEY2PIMID 0.7 15.2
19 EIAV CA2X QKMML2LAKAL 0 11.8
20 EIAV NC2p9 QKQTF2PIQQK 0.01 0
21 EIAV PR2RT AKLVL2AQLSK 0 13.4
22 EIAV RT2UT KEEIM2LAYQG 0.01 18.3
23 RSV MA2p2A GTSCY2CHGTA 0 2.5e
24 RSV p2B2p10 PPYVG2SGLYP 0 0f
25 RSV p102CA PVVAM2PVVIK 0.1 0
26 RSV CA2p3 IAAAM2SSAIQ 0 0
27 RSV p32NC IQPLIM2AVVNR 100 318e
28 RSV NC2PR PPAVS2LAMTM 0 0.13e
29 RSV PR2RT RATVL2TVALH 0.3 1.9e
30 RSV RT2IN TFQAY2PLREA 0 0.18d
31 MMTV MA2pp21 SDLVL2LSAEARRg 0 6.9
32 MMTV pp212p3 DSKAF2LADTW 0 7.5
33 MMTV p32p8 DELIL2PVKRK 2.6 1.5
34 MMTV p82n PPVGFAG2AMA 0 0.01h
35 MMTV n2CA LTFTF2PVVFMRRg 0.01 0.9
36 MPMV p122CA PKDIF2PVTET 0.2 0.2
37 BLV MA2CA PPAIL2PIISE 164.5i 0.3
38 BLV CA2NC KQPAIL2VHTPG 0 0
39 BLV TF2PR ELECL2LSIPL 0 8.5
40 BLV PR2p13 PPMVG2VLDAP 0.7i 0.04
41 MuLV MA2p12 PRSSLY2PALTP 0 0.2
42 MuLV p122CA TSQAF2PLRAG 0 8.7
43 MuLV CA2NC MSKLL2ATVV 0 j 0
44 MuLV NC2PR TQTSLL2TLDDQ 0 0
45 MuLV PR2RT PLQVL2TLNIERRf 0.1 0
46 MuLV RT2IN TSTLL2IENSS 0 0k
47 HTLV-1 MA2CA APQVL2PVMHP 85.2d 16.1d
48 HTLV-1 CA2NC KTKVL2VVQPK 150.6d 14.3d
49 HTLV-1 TF12PR DPASIL2PVIP 3.8d 0
50 HTLV-1 PR2Px KGPPVIL2PIQAP 288.3d 8.4d
a Nomenclature of the retroviral proteins is according to Leis et al. (58).
b Taken from Ref. 30.
c Taken from Ref. 20.
d Taken from Ref. 5.
e Taken from Ref. 32.
f This peptide inhibited HIV-1 PR with a Ki of 20 M.
g Residues that were added to the cleavage site sequences to enhance the solubility of the peptides are underlined.
h This peptide inhibited HIV-1 PR with a Ki of 14 M.
i Taken from Ref. 33.
j This peptide inhibited HTLV-1 PR with a Ki of 61 M.
k This peptide inhibited HIV-1 PR with a Ki of 12 M.
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peptide showed inhibitory effect on HTLV-1 PR and three on
HIV-1 PR, with Ki values being in the micromolar range (see
legend of Table I). These results indicated a substantially
broader specificity of the HIV-1 PR.
Mutations Introduced to the HTLV-1 Protease—The se-
quence alignment of HTLV-1 and HIV-1 PRs based on the
multiple alignments of PRs with known structures is shown in
Fig. 1A (10). The kinetic data have been analyzed using a
molecular model of HTLV-1 PR (10) and a crystal structure of
the HIV-1 PR-inhibitor complex (28). The substrate-binding
site of PR is comprised mainly by residues located at three
regions: the active site region, the flap region that closes down
on the bound ligand, and the C-terminal region at the shoulder
of the substrate-binding site (Fig. 1B). The active site region is
very conserved in retroviral PRs; it contains only one amino
acid substitution between HTLV-1 and HIV-1 PRs; the residue
corresponding to HTLV-1 PR Met-37 is Asp in HIV-1 PR. The
same residue differs in other retroviral PRs. Unlike the active
site region, most of the residues of the flap and C-terminal
regions are different in the two PRs (Fig. 1A). In this study, 15
HTLV-1 PR mutants were generated by replacing key residues
of the substrate-binding pockets with the structurally equiva-
lent residues of HIV-1 PR. These mutations included M37D,
V56I, L57G, A59I, F67Q, N96T, N97P, and W98V (Fig. 1 and
Table II). Because the residue corresponding to Met-37 is an
important determinant of specificity in PRs (27), hydrophobic
residues of various sizes (Ala, Val, and Ile) as well as the
drug-resistant mutation Asn of HIV-1 PR were introduced at
this position (Table II). Three mutants with combined substi-
tutions at the flap and C-terminal regions were also tested. The
mutant PRs were purified to homogeneity from inclusion bod-
ies and folded as described previously for wild type PRs (5, 28).
Activities of the Mutant HTLV-1 Proteases against a Peptide
Substrate and Their Autoprocessing Capabilities from MBP Fusion
Protein—The peptide representing the capsid2nucleocapsid cleav-
age site of HTLV-1 was shown to be a good substrate of both wild
type HTLV-1 and HIV PRs (Ref. 5, Table I and Table II). Eight of
15 HTLV-1 PR mutants were able to hydrolyze this substrate,
although mostly with dramatically reduced kinetic efficiency as
compared with the two wild type enzymes (Table II). However, the
Km values obtained with some mutants were similar to those ob-
tained with the wild type enzymes, whereas some other mutants
showed moderately increased values. Because many of the mutants
showed very low activity and loss of inhibitor potency, active site
titration was possible only for M37V, M37I, and the mutant having
HIV-1 PR-like flap (Table II). Comparison of the active protein
content with the total amount of protein suggested that the folding
efficiency of these mutants is much lower as compared with the
wild type enzymes. These results also suggest that the lack of
activity of some mutants may be the consequence of the inability to
refold properly.
To further verify the low activity/improper refolding capabil-
ity of the mutants, they were also expressed as MBP fusion
proteins, from which the wild type enzyme is capable of self-
processing itself out (Fig. 3). An advantage of expressing a
protein in fusion with MBP is that it is very effective to promote
the solubility of polypeptides to which it is fused, compared
with other commonly used proteins like glutathione S-trans-
ferase and thioredoxin (47, 48). All of the mutants that ap-
peared to be inactive after folding from inclusion bodies using
the pET expression system were also expressed in fusion with
MBP. Unlike the wild type enzyme as well as the mutant
having HIV-1 PR-like flap, none of those mutants were capable
of self-processing during expression (Fig. 3).
Mutations Affecting Mainly the S4/S2-binding Sites of
HTLV-1 Protease—The S4 subsite is close to the surface of the
enzyme and is partly exposed to solvent for all retroviral PRs.
In contrast, the S2 subsites are relatively small and formed by
mostly hydrophobic residues and consequently would be ex-
pected to accommodate smaller hydrophobic P2 residues. How-
ever, whereas HIV-1 PR preferred more polar amino acids at
P2 (and P2), all other PRs including HTLV-1 PR preferred
hydrophobic residues (10, 27, 49).
Residues forming the S4-binding sites of the HTLV-1 and
HIV-1 PRs include Met-37/Asp-30, Ser-55/Met-46, Val-56/Ile-
47, Leu-57/Gly-48, and Val-92/Leu-76 with very distal contri-
butions from Phe-67/Gln-58 and the Pro-7 to Ala-8 insertion in
HTLV-1 PR (Fig. 2, Ref. 10). Asp-30 of HIV-1 PR and structur-
ally equivalent residues of other PRs were shown to be impor-
tant determinants for the different specificities of the PRs at S4
and S2 (23, 24). In another example, HIV PR mutant Asn-30,
harboring a mutation appearing in nelfinavir resistance,
showed specificity changes compared with wild type enzyme
(19) accompanied by small structural changes in PR-substrate
interactions (28). Therefore, HTLV-1 PR Met-37 was substi-
tuted by Asp, Asn, Ala, Val, and Ile. Most interesting, the
mutants containing Asp-37 or Asn-37 were inactive on all sub-
strates tested (not shown). They were also not able to self-
process themselves from MBP fusion proteins (Fig. 3). Substi-
tuting the smaller Ala in this position also rendered the
enzyme inactive on most of the substrates (not shown), except
for the substrate with Phe at P1, which was the best substrate
for the wild type enzyme (10), suggesting that proper hydro-
phobic interactions at this position of HTLV-1 PR are required
for efficient catalysis. The other mutants with conserved sub-
stitutions (Val or Ile) at residue 37 still showed substantially
reduced kcat values without an apparent change of Km values as
shown for the wild type substrate (Table I). The specificity of
these mutants was also substantially altered. Both preferred
P4 Ile as compared with the P4 Val preference for the wild type
HTLV-1 PR (Fig. 4A), similar to the HIV-1 PR. However, they
also preferred Leu over Val at this position, which is not seen
with either of the wild type PRs. Val-56 of HTLV-1 is part of the
flap region, and Ile is the equivalent residue in HIV-1 PR. The
V56I mutant was a very inefficient enzyme (Table I), but it
hydrolyzed the P4 Leu substituted peptide with a substantially
increased rate (Fig. 4A), suggesting that the larger side chain of
Leu at P4 was able to make better hydrophobic interactions
with V56I than the other smaller side chains of Val, Thr, and
Ile at P4. The order of P4 side chain preference of the mutant
having HIV-1 PR-like flap resembled that of the wild type
HIV-1 PR, except it did not hydrolyze well with the substrate
having Ala at this position (Fig. 4A).
The S2 subsite shows differences in residues Met-37/Asp-30,
Val-56/Ile-47, Ala-59/Ile-50, and Val-92/Leu-76 for HTLV-1 and
HIV-1 PRs (Fig. 2) (10). These differences result in a somewhat
larger, more hydrophobic S2 subsite in HTLV-1 PR as com-
pared with HIV-1 PR. Most interesting, both M37V and M37I
mutations changed the Val3 Leu3 Ile P2 preference to Ile3
Val 3 Leu, the same as observed for HIV-1 PR; however, they
were not able to hydrolyze the substrate containing bulky ar-
omatic Phe at this position (Fig. 4B). Introduction of
-branched residues into this position may restrict the size of
the side chain, which can fit into this subsite. Similar to the
findings obtained with the P4-modified substrate, the mutant
having the HIV-1 PR-like flap showed a P2 specificity more
similar to that of HIV-1 PR than HTLV-1 PR, but this mutant
also did not tolerate Phe at this position, likely due the two
-branched residues introduced into the sequence (Fig. 4B).
These results suggested that the flap region is important not
only for the enzyme activity (27) but also for the specificity
differences of the two wild type PRs.
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FIG. 1. A, alignment of HTLV-1 and HIV-1 PR sequences. HTLV-1 PR T1 and T2 represent different positions of Thr-54 for modeling subunit
1 and 2, respectively (10). Residues of the PRs that are involved in the substrate binding are shown in boldface. Residues mutated to stabilize the
enzymes from autoproteolysis are underlined. HTLV-1 and HIV-1 proteases used in this study contained three mutations (L40I, C90A, and C119A)
and five mutations (Q7K, L33I, L63I, C67A, and C95A), respectively. Previous studies demonstrated that the specificity of these mutated enzymes
was identical to the specificity of nonstabilized forms (5, 19). B, ribbon model of HTLV-1 PR. Position of the residues that were mutated in this study
is indicated by a ball-and-stick representation. Residues are labeled only for the first monomer.
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Mutations Affecting the S3/S1-binding Sites of HTLV-1 Pro-
tease—The S3 subsite is usually large and is similar to S4 in
being partly exposed to solvent at the surface of the enzyme.
Consequently, the P3 side chain may be positioned either to
interact with the more polar residues of the PR surface or to
interact with the hydrophobic internal residues of the enzyme.
Several P3-substituted substrates were hydrolyzed by both
wild type PRs, indicating that this site is not restrictive, but
although HTLV-1 PR preferred the original Lys-containing
substrate, HIV-1 PR preferred larger hydrophobic residues
(Fig. 5A) (10). Analysis of the HIV-1 PR crystal structure and
the model structure for HTLV-1 PR suggested that about half
of the residues participating in the S3-P3 interactions are
identical in both enzymes (10). The S3 subsites differ in resi-
dues Leu-57/Gly-48 and Ala-59/Ile-50 from the flap, whereas
Asn-96/Thr-80, Asn-97/Pro-81, and Trp-98/Val-82 residues
from the other subunit form one side of the subsite. Wild type
HTLV-1 PR was less sensitive to P3 changes (Fig. 5A) (10),
whereas Leu-57 and Trp-98 were predicted to interact favor-
ably with hydrophobic residues, Asn-96 and Asn-97 can po-
tentially interact with polar P3 residues, including Lys of the
unmodified substrate. Both L57G and A59I flap mutants were
very inefficient enzymes on the unsubstituted peptide (Table I).
Leu-57 is predicted to interact favorably with larger hydropho-
bic P3 residues in the wild type HTLV-1 PR, and this interac-
tion appears to be important for efficient hydrolysis. Although
P3 substitutions did not substantially improve the hydrolysis
for the L57G mutant, surprisingly the P3 Ala-substituted pep-
tide was the best substrate for this enzyme (not shown). Unlike
the L57G mutant, introduction of larger hydrophobic residues
TABLE II
Description of the mutant enzymes, affected substrate-binding sites, and kinetic parameters for the hydrolysis of the HTLV-1
capsid2nucleocapsid cleavage site peptide (KTKVL2VVQPK)
Enzyme Affected siteor regiona
Folding
efficiencyb Km kcat kcat/Km
% mM s1 mM1 s1
HTLV-1 PR (wt)c 100 0.063 10.0 158.7
HIV-1 PR (wt)c 100 0.16 3.6 22.5
HTLV-1 PR (M37D) S4, S2 NDd Not hydrolyzede
HTLV-1 PR (M37N) S4, S2 ND Not hydrolyzed
HTLV-1 PR (M37A) S4, S2 ND Not hydrolyzed
HTLV-1 PR (M37V) S4, S2 63 0.040 0.11 2.78
HTLV-1 PR (M37I) S4, S2 4 0.060 0.17 2.90
HTLV-1 PR (V56I) S4, S2 ND ND  0.001 ND
HTLV-1 PR (L57G) S4, S3, S2 ND Not hydrolyzed
HTLV-1 PR (A59I) S3, S2, S1 ND 0.438 (0.021) (0.05)
HTLV-1 PR (F67Q) S4 ND Not hydrolyzed
HTLV-1 PR (N96T) S3, S1 ND 0.301 (0.007) (0.02)
HTLV-1 PR (N97P) S3, S1 ND 0.127 (0.002) (0.02)
HTLV-1 PR (W98V) S3, S1 ND 0.200 (0.002) (0.01)
HTLV-1 PR (V56I/L57G/A59I) All 24 0.155 1.68 10.87
HTLV-1 PR (N96T/N97P/W98V) S3, S1 ND Not hydrolyzed
HTLV-1 PR (V56I/L57G/A59I/N96T/N97P/W98V) All ND Not hydrolyzed
a Note that due to the symmetrical homodimeric nature of the PR, the respective primed binding sites (like S4, S2, etc.) are also affected by the
mutation(s), but these sites were not probed in this study.
b Folding efficiency was calculated from the ratio of active enzyme determined by using active site titration and total protein amount. For
enzymes with low detectable activity, it was not possible to determine this ratio, for these mutants the catalytic constants calculated from the
protein content are given in parentheses.
c These data are taken from Ref. 10.
d Not determined.
e No hydrolysis was observed when incubated with 0.4 M PR for 20 h at 37 °C.
FIG. 2. A schematic representation
of the HTLV-1 capsid2nucleocapsid
substrate in the S4-S3 subsites of PR.
The relative size of each subsite is indi-
cated approximately by the area enclosed
by the curved line around each substrate
side chain. PR residues forming the sub-
sites are shown only for those that differ
between the two PRs as HTLV-1/HIV-1
residues. Residues of HTLV-1 that were
mutated in this study are underlined.
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into P3 dramatically improved the specificity constants for the
A59I mutant; the Ile side chain in this position was predicted to
make more hydrophobic contacts with hydrophobic P3 side
chains as compared with the original Ala residue. The A59I
mutant showed a preference for Phe at P3, consistent with
additional favorable hydrophobic interactions. Substitution of
Asn-96 to Thr and Asn-97 to Pro increased the relative prefer-
ence toward hydrophobic P3 residues over Lys at P3 (Fig. 5A).
Unexpectedly, the W98V mutant did not have a preference
toward larger hydrophobic residues, it rather preferred smaller
hydrophobic ones (Fig. 5A).
The S1 subsite shows differences in Ala-59/Ile-50, Asn-96/
Thr-80, Asn-97/Pro-81, and Trp-98/Val-82 in HIV-1 and
HTLV-1 PRs (10). Despite these sequence differences, the
structure and the specificity at the S1 subsite of the two PRs
appears to be similar (10). The S1 subsite is a relatively large
and hydrophobic internal pocket in the enzyme. The best sub-
strate for both enzymes had Phe at P1 (10). Unexpectedly,
A59I, N97P, and W98V mutants preferred P1 Met instead of
the P1 Phe preferred by both wild type PRs (Fig. 5B). These
substitutions introduced -branched side chains, or conforma-
tional restraints in case of Pro, which may restrict the fit of the
large bulky Phe P1 side chain within the subsite.
The specificity of the mutant having HIV-1 PR-like flap
resembled the specificity of HIV-1 PR on both P3 and P1;
however, it also had some unique features, for example the best
P3 substitution was Leu and the mutant did not favor Phe at
P1 or P1.
Inhibition Profile of the Wild type and Mutant HTLV-1 Pro-
teases—Several potent inhibitors that target HIV-1 PR are
used in clinical practice. These include indinavir, saquinavir,
nelfinavir, ritonavir, and amprenavir. We have tested these
inhibitors and two reduced peptide-containing HTLV-1 inhibi-
tors on the wild type and the mutant HTLV-1 PRs. The assays
were performed in a high-throughput microtiter plate fluores-
cent assay system (35). Except for indinavir, the HIV-1 PR
inhibitors were not effective against the wild type HTLV-1 PR
(Fig. 6). We have previously tested several inhibitors of HIV-1
PR, including saquinavir, as inhibitors of the HTLV-1 PR by
using the very labor-intensive and time-consuming HPLC as-
say. Only compound 3 inhibited the PR up to 10 M (5). Four of
the HIV-1 PR inhibitors used in clinical practice were also
tested on HTLV-1 Gag processing in vitro and did not show any
FIG. 4. Relative specificity constants of the wild type and mu-
tant HTLV-1 proteases for peptides having P4 (A) and P2 (B)
substitutions in the HTLV-1 capsid2nucleocapsid substrate se-
quence. Original P4 residue (Thr) of the substrate (KTKVL2VVQPK)
is underlined. Values are calculated as kcat/Km values relative to the
unmodified substrate. The detection limit of the relative kcat/Km values
for the wild type PRs was 0.001. Because of the low activity of the
mutants, the detection limit of the relative kcat/Km values for M37V,
M37I, V56I, and the triple mutant were 0.01, 0.7, 0.7, and 0.01,
respectively.
FIG. 3. Expression of the HTLV-1
protease mutants as MBP fusion pro-
teins. A, schematic representations of the
fusion proteins used in this study. The
8-residue N-terminal flanking sequence
allows the protease to process itself out of
the fusion protein. B, self-processing ca-
pability of mutant HTLV-1 proteases. Fu-
sion proteins were expressed in E. coli
cells, and the self-processing capability of
the proteases was analyzed by immuno-
blotting using anti-HTLV-1 PR antisera.
Mutations in the HTLV-1 PR coding re-
gions are indicated above the lanes. Side,
N96T/N97P/W98V; flap, V56I/L57G/
A59I; sideflap, V56I/L57G/A59I/N96T/
N97P/W98V. As a control, pMal-c2 vector
expressing only MBP was used for trans-
formation and expression (labeled as
mock).
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effect (50). These results demonstrate the large differences in
specificity of the two enzymes. The most potent inhibitor of the
HTLV-1 PR in our previous studies was a statine-containing
inhibitor, based on the matrix2capsid cleavage site sequence
of HTLV-1. In contrast, the statine-containing peptide based on
the capsid2nucleocapsid cleavage site sequence did not inhibit
the enzyme (5). Here we have tested two reduced peptide bond-
containing inhibitors of the HTLV-1 PR, IB268 and IB269, with
the sequences of the HTLV-1 capsid2nucleocapsid and
matrix2capsid cleavage sites, respectively. Our previous stud-
ies on HIV-1 and HIV-2 PRs indicated that reduced peptide
bond-containing substrate analogs act as potent inhibitors of
the retroviral proteinases in the presence of high salt (30).
IB268 and IB269 were potent inhibitors of the wild type
HTLV-1 PR in the HPLC assay, with Ki values below 50 nM
(35). They were also the best inhibitors of the wild type HTLV-1
PR in the fluorometric assay, which was performed in a sub-
stantially lower ionic strength (Fig. 6).
FIG. 5. Relative specificity constants
of the wild type and mutant HTLV-1
proteases for peptides having P3 (A)
and P1 (B) substitutions in the HTLV-1
capsid2nucleocapsid substrate se-
quence. Original P3 residue (Lys) of the
substrate (KTKVL2VVQPK) is underlined.
Values are calculated as kcat/Km values rel-
ative to the unmodified substrate. The detec-
tion limit of the relative kcat/Km values for
the wild type PRs was 0.001. Because of the
low activity of the mutants, the detection
limit of the relative kcat/Km values for A59I,
N96T, N97P, W98V, and the triple mutant
were 0.3, 0.7, 0.7, 0.7, and 0.01, respectively.
FIG. 6. Inhibition of wild type and
mutant HTLV-1 proteases by clini-
cally used HIV-1 PR inhibitors as
well as HTLV-1 cleavage site analogs.
A fluorescent substrate having the se-
quence of the HTLV-1 capsid/nucleocap-
sid cleavage site was used to measure the
inhibition of the proteases. Ki values were
determined according to Williams and
Morrison (34).
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Most of the HTLV-1 PR mutants were not inhibited by the
HIV-1 PR inhibitors; only the enzyme having an HIV-1 PR-like
flap showed some degree of sensitivity toward some of the
HIV-1 PR inhibitors, although it showed decreased affinity
toward the HTLV-1 PR inhibitors (Fig. 6). The large effect of
the V56I mutation on inhibitor susceptibility is in good agree-
ment with previous findings (4) that the corresponding I47V
mutation appears in drug resistance in vitro. This residue
seems to be important for defining the differences in inhibitor
susceptibility of the HIV-1 and HTLV-1 PRs.
DISCUSSION
The specificity of HTLV-1 and HIV-1 proteases was com-
pared by using oligopeptides representing maturation cleavage
sites in various retroviruses. Based on the results, the specific-
ity of HTLV-1 PR appears to be substantially narrower as
compared with the specificity of HIV-1 PR. Cleavage site se-
quences of HTLV-1 PR appear to be more “ancient” than those
in HIV-1; distantly related retro-elements, like Ty3 or Ty1
which are evolutionarily much more conserved than infectious
retroviruses, also contain -branched residues at P2 and P2,
although the P1 and P1 residues are typically smaller and less
hydrophobic than the residues in HTLV-1 and HIV-1 cleavage
sites (51, 52). Although the highest specificity constants were
obtained with the RSV p32nucleocapsid protein cleavage site
peptide (Table I), this peptide behaved anomalously. The in-
crease of the substrate concentration caused a decrease in
activity (data not shown), likely due to nonproductive binding,
and therefore we have selected the capsid2nucleocapsid cleav-
age site (KTKVL2VVQPK) for developing a fluorescent assay
for both proteinases. This peptide was also found to be a sub-
strate for the HIV-2, EIAV, and BLV proteases2; therefore, it
may also serve as a starting sequence for a general retroviral
PR assay.
To characterize further the specificity of HTLV-1 PR, muta-
tions were introduced into its ligand-binding sites. Many of the
mutants we have generated were either inactive or possessed
scarcely detectable activity and loss of capability to self-process
from an MBP fusion protein. Based on active site titration, the
folding efficiency of the active mutants is much lower as com-
pared with the wild type enzymes. In the case of HIV-1 PR,
similar to the wild type HTLV-1 PR, close to 100% folding
efficiency was observed (5, 22). Many HIV-1 PR forms with
drug-resistant mutations had a similar folding efficiency and
also comparable catalytic efficiency to that of wild type PR
(17–20). However, in the case of some single mutants of HIV-1
PR, we observed substantial reduction (40–90%) in folding
efficiency2 (20), suggesting that although the wild type se-
quence appears to be optimal, even single mutations may have
substantial effect on the protease folding, which may influence
the viability of the mutant viruses harboring these mutant
protease sequences.
The activity of four single mutants harboring HIV-like resi-
dues (M37D, M37N, L57G, and F67Q) was undetectable in the
assays. Mutation to Asp of the residue corresponding to HIV-1
PR Met-37 of murine leukemia virus PR (His) and RSV PR (Ile)
resulted in enzymes that showed specificity constants close to
those of the respective wild type PRs (23, 24). On the other
hand, mutation to Asp of the corresponding Ile residue of FIV
PR resulted in an inactive mutant (25). The side chain of the
corresponding HIV-1 Asp residue in HIV-1 PR crystal struc-
tures points toward the solvent, but it turns inward in crystal
structures with P2 Glu residues and interacts with that side
chain (53). This Asp residue is also part of one of the regions
involved in the cooperative folding and stability of HIV-1 PR
(54). There is a hydrophobic cluster in the S4/S4-binding site of
all retroviral PRs with known crystal structure (HIV-1, HIV-2,
SIV, EIAV, FIV, and RSV PRs). It seems that the residue in
retroviral PRs corresponding to Met-37 of HTLV-1 PR can be
changed without any deleterious effect if the cluster is com-
posed of at least 4 side chains as is the case for HIV-1, HIV-2,
SIV, EIAV, and RSV PRs. However, if this hydrophobic cluster
is formed by only 3 residues as in FIV PR and HTLV-1 PRs, the
hydrophobic nature of Met-37 of HTLV-1 PR or the correspond-
ing Ile of FIV PR may be crucial for stabilizing the structure or
for the folding pathway.
Leu-57 is part of the flap. Mutation of the corresponding Ile
of FIV PR and EIAV (25, 26), as well as His of avian myelo-
blastosis virus/RSV PR (22), also resulted in inactive enzymes,
although the HIV-1 PR was able to accommodate Ile, His, and
various other amino acid residues in place of Gly at this posi-
tion (55), and its mutation to Val occurs in saquinavir and
indinavir resistance (4). Phe-67 in HTLV-1 was predicted to
contribute to the S4-binding pocket (10). The corresponding
Gln residue is not subject to natural variations (except that it
is replaced by Glu in some cases) and to resistant mutations (4),
indicating that it may be a structurally important residue.
When residues of the feline immunodeficiency virus (FIV PR)
or murine leukemia virus PR were changed to the equivalent
residues of HIV-1 PR, many of the mutants had catalytic effi-
ciency close to that of the wild type enzyme (24, 25). Although
no folding efficiency data were reported for these mutants, the
catalytic efficiency implied that their folding capability was not
substantially less than that of the respective wild type en-
zymes. Whereas most of the RSV PR mutants as well as the
wild type enzyme refolded with similar efficiencies (18–30%),
some mutants showed even higher catalytic activity than the
wild type RSV PR (23). Based on our results, the specificity of
HTLV-1 PR is narrower than that of HIV-1 PR, and both the
folding pathway and the catalytic efficiency of HTLV-1 PR is
apparently much more sensitive toward mutations than those
of other retroviral PRs, especially HIV-1 PR. In this aspect it is
important to note that after infection HTLV-1 typically repli-
cates by cell division and not by producing exogenous virions,
omitting the error-prone reverse transcription step. Therefore,
HTLV-1 is much more conserved than HIV-1 (56). As a conse-
quence, the HTLV-1 PR has not undergone the rapid evolution
that was able to optimize the HIV-1 PR for both high catalytic
efficiency as well as flexibility in tolerating mutations under
selective pressure.
The most active mutant was the one containing the complete
flap substitution, although the enzymes bearing the individual
L57G and A59I mutants were very inefficient enzymes. Our
previous studies (27) indicated the importance of the flap re-
gion for catalytic activity of HIV PR, but it did not appear to
have a major role in determining substrate specificity. A com-
parative mutational study on HIV-1 and HIV-2 PRs also sug-
gested that the C-terminal region was important for the differ-
ential activity of the enzymes (21). The mechanism of
resistance due to mutation of Gly-48 of the HIV-1 PR flap was
suggested to be an alteration of the flap mobility instead of
changing the enzyme-ligand interactions (57). The results pre-
sented here suggest that the flap region has an important role
in determining the differences in both substrate specificity and
inhibitor susceptibility of the HTLV-1 and HIV-1 proteases.
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